Skip to main content
Fig. 3 | BMC Rheumatology

Fig. 3

From: Circulating exo-miRNA-27a-5p is a novel biomarker of the tofacitinib treatment response in rheumatoid arthritis

Fig. 3

Validation of candidate targets of circulating exomiRNAs. (a–d) Relative levels of four circulating exomiRNAs in the validation group. (e) Receiver operating characteristic (ROC) curve of four circulating exomiRNAs for RA. The values are normalized to Cel-miRNA-39-3p and shown on a log10 scale on the 𝑦-axis. All data are shown as mean ± SD. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us